|
|
Article: Center for Inherited Disease Research (CIDR) to Use Illumina Whole-Genome Genotyping Solutions to Support Study for Finland-United States Type 2 Diabetes Collaboration.
- Article from:
- Business Wire
- Article date:
- January 11, 2006
CopyrightCOPYRIGHT 2006 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Data from Illumina BeadChips and Infinium(TM) Assay Reagents Will Help Identify Genetic Variants that Predispose Individuals to Type 2 Diabetes
Illumina, Inc. (NASDAQ:ILMN) announced today that it is partnering with the Center for Inherited Disease Research (CIDR) to use the Sentrix(R) HumanHap300 BeadChip and Infinium(TM) Assay for a pilot study of Type 2 Diabetes. One goal of this study is to evaluate the Illumina technology for possible adoption as the standard platform for CIDR's genome-wide association service to be offered to the scientific community in the spring of 2006.
CIDR is working with Illumina to genotype over 2500 ...